Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment
作者： Rakesh K. Jain , Dan G. Duda
DOI: 10.1007/978-3-540-33177-3_33
关键词:
摘要: Surpassing several setbacks, the clinical development of antiangiogenic agents has accelerated remarkably over past 3–4 years. As a result, there are currently three direct blockers VEGF pathway approved for use in cancer, and two others age-related wet macular degeneration. Other that block advanced stages have shown promising results. With these exciting developments come critical questions regarding new molecularly targeted agents, alone or combination with standard cytotoxic agents.
springer.com
springerlink.com参考文章(49)
Rakesh K. Jain, Antiangiogenic Therapy for Cancer: Current and Emerging Concepts Oncology. ,vol. 19, pp. 7- 15 ,(2005)
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
Rakesh K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine. ,vol. 7, pp. 987- 989 ,(2001) , 10.1038/NM0901-987
Philippe Martinive, Bernard Gallez, Christine Baudelet, Pierre Sonveaux, Réginald Ansiaux, Nelson Beghein, Olivier Feron, Bénédicte F. Jordan, Vincent Grégoire, Julie De Wever, Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment Clinical Cancer Research. ,vol. 11, pp. 743- 750 ,(2005)
Alexei V Salnikov, Pernilla Roswall, Christian Sundberg, Humphrey Gardner, Nils-Erik Heldin, Kristofer Rubin, Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Laboratory Investigation. ,vol. 85, pp. 512- 521 ,(2005) , 10.1038/LABINVEST.3700252
Donald P. Bottaro, Lance A. Liotta, Cancer: Out of air is not out of action. Nature. ,vol. 423, pp. 593- 595 ,(2003) , 10.1038/423593A
Ricky T. Tong, Yves Boucher, Sergey V. Kozin, Frank Winkler, Daniel J. Hicklin, Rakesh K. Jain, Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors Cancer Research. ,vol. 64, pp. 3731- 3736 ,(2004) , 10.1158/0008-5472.CAN-04-0074
Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108
Jérome Segers, Vincent Di Fazio, Réginald Ansiaux, Philippe Martinive, Olivier Feron, Pierre Wallemacq, Bernard Gallez, Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Letters. ,vol. 244, pp. 129- 135 ,(2006) , 10.1016/J.CANLET.2005.12.017
Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler, Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nature Reviews Clinical Oncology. ,vol. 3, pp. 24- 40 ,(2006) , 10.1038/NCPONC0403